These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 30942465

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
    Fan CN, Ma L, Liu N.
    J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
    [Abstract] [Full Text] [Related]

  • 3. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L.
    Clin Cancer Res; 2015 Mar 01; 21(5):1207-14. PubMed ID: 25547678
    [Abstract] [Full Text] [Related]

  • 4. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ.
    Breast Cancer Res; 2017 Dec 19; 19(1):133. PubMed ID: 29258605
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
    Yang R, Xing L, Wang M, Chi H, Zhang L, Chen J.
    Cell Physiol Biochem; 2018 Dec 19; 50(2):473-488. PubMed ID: 30308479
    [Abstract] [Full Text] [Related]

  • 7. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
    Zhao Y, Song Y, Zhang Y, Ji M, Hou P, Sui F.
    Mol Cell Probes; 2023 Dec 19; 72():101940. PubMed ID: 37871689
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B, Xie X.
    Breast Cancer Res; 2017 Jun 19; 19(1):72. PubMed ID: 28629464
    [Abstract] [Full Text] [Related]

  • 11. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
    Turkistani S, Sugita BM, Fadda P, Marchi R, Afsari A, Naab T, Apprey V, Copeland RL, Campbell MC, Cavalli LR, Kanaan Y.
    BMC Cancer; 2021 Jul 27; 21(1):861. PubMed ID: 34315420
    [Abstract] [Full Text] [Related]

  • 12. miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes.
    Uva P, Cossu-Rocca P, Loi F, Pira G, Murgia L, Orrù S, Floris M, Muroni MR, Sanges F, Carru C, Angius A, De Miglio MR.
    Int J Med Sci; 2018 Jul 27; 15(6):536-548. PubMed ID: 29725243
    [Abstract] [Full Text] [Related]

  • 13. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S, Gabło N, Barnaś E, Szybka M, Morawiec J, Kołacińska A, Zawlik I.
    Ginekol Pol; 2017 Jul 27; 88(10):530-536. PubMed ID: 29192413
    [Abstract] [Full Text] [Related]

  • 14. Impact of three miRNA signature as potential diagnostic marker for triple negative breast cancer patients.
    Kumar V, Gautam M, Chaudhary A, Chaurasia B.
    Sci Rep; 2023 Dec 08; 13(1):21643. PubMed ID: 38062163
    [Abstract] [Full Text] [Related]

  • 15. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A, Al-Tweigeri T, Alkhayal W, Suleman K, Tulbah A, Amer S.
    Genes (Basel); 2021 Apr 09; 12(4):. PubMed ID: 33918859
    [Abstract] [Full Text] [Related]

  • 16. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
    Hong HC, Chuang CH, Huang WC, Weng SL, Chen CH, Chang KH, Liao KW, Huang HD.
    Theranostics; 2020 Apr 09; 10(19):8771-8789. PubMed ID: 32754277
    [Abstract] [Full Text] [Related]

  • 17. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
    Zhang M, Zhang F, Wang J, Liang Q, Zhou W, Liu J.
    J Transl Med; 2024 May 04; 22(1):423. PubMed ID: 38704606
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y, Li L.
    Oncotarget; 2017 Mar 21; 8(12):19455-19466. PubMed ID: 28038450
    [Abstract] [Full Text] [Related]

  • 19. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
    Yang F, Zhang W, Shen Y, Guan X.
    Int J Oncol; 2015 Mar 21; 46(3):927-32. PubMed ID: 25571912
    [Abstract] [Full Text] [Related]

  • 20. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.
    Hu Y, Zou D.
    PLoS One; 2021 Mar 21; 16(12):e0260811. PubMed ID: 34965257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.